Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).

被引：1
|
作者：
Barata, Pedro C.
Emamekhoo, Hamid
Mendiratta, Prateek
Gopalakrishnan, Dharmesh
Koshkin, Vadim S.
Tyler, Allison Janine
Ornstein, Moshe Chaim
Grivas, Petros
Gilligan, Timothy D.
Rini, Brian I.
Kyriakopoulos, Christos
Garcia, Jorge A.
机构：
[1] Cleveland Clin, Cleveland, OH USA
[2] Univ Wisconsin, Madison, WI USA
[3] Cleveland Clin Taussig Canc Insitute, Cleveland, OH USA
[4] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Y.
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [22] Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 66 - 66
  • [23] A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
    Ye, Ding-Wei
    Gu, Weijie
    Han, Weiqing
    Luo, Hong
    Zhou, Fangjian
    He, Dalin
    Ma, Lulin
    Guo, Hongqian
    Liang, Chaozhao
    Chong, Tie
    Jiang, Jun
    Chen, Zhiwen
    Wang, Yong
    Zou, Qing
    Tian, Ye
    Xiao, Jun
    Huang, Jian
    Yang, Xinfeng
    Li, Junliang
    Jin, Chunlei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
    Gill, David Michael
    Stenehjem, David D.
    Cheng, Heather H.
    Kessler, Elizabeth Riley
    Hahn, Andrew W.
    Gupta, Sumati
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [25] Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
    Shore, Neal D.
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS
    Tombal, B.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Gratzke, C.
    Grabbert, M.
    Vilaseca, A.
    Shore, N.
    Kopyltsov, E.
    Boegemann, M.
    Kapur, S.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Joensuu, H.
    Smith, M. R.
    Hussain, M.
    EUROPEAN UROLOGY, 2023, 83
  • [27] Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial
    Burgess, Earle F.
    Grigg, Claud M.
    Boselli, Danielle
    Symanowski, James T.
    Golshayan, Alireza
    Graham, David L.
    Osei-Boateng, Kwabena
    Gavini, Nagajyothi
    Zhu, Jiang
    Brown, Landon C.
    Norek, Sarah
    Begic, Xhevahire J.
    Raghavan, Derek
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
  • [28] Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial
    Saad, F.
    Vjaters, E.
    Shore, N. D.
    Olmos, D.
    Xing, N.
    Gomes, A. J. P. D. S.
    Mota, A. C. A.
    Salman, P.
    Jievaltas, M.
    Ulys, A.
    Jakubovskis, M.
    Kopyltsov, E.
    Han, W.
    Nevalaita, L.
    Testa, I.
    Le Berre, M-A.
    Kuss, I.
    Kunhiparambath, H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1257 - 1258
  • [29] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Schwentner, Christian
    AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
  • [30] Darolutamide (DARO) in combination with androgendeprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
    Wang, S.
    Fu, C.
    Li, Y.
    Xing, J.
    Zhou, L.
    Yang, Y.
    Wang, H.
    Smith, M. R.
    Tombal, B.
    Hussain, M.
    Niu, Y.
    Cai, L.
    Liu, Q.
    Littleton, N.
    Li, R.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1572 - S1572
12345